紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效观察

摘要

OBJECTIVE:To probe into the efficacy and safety of paclitaxel combined with oxaliplatin in treatment of advanced and recurrent cervical cancer.METHODS:90 patients with advanced and recurrent cervical cancer admitted into Longyan the First Hospital Affiliated to Fujian Medical University from Feb.2011 to Mar.2012 were selected to be divided into observation group and control group via the random number table,with 45 cases in each.The control group was treated with paclitaxel combined with cisplatin,while the observation group received paclitaxel combined with oxaliplatin.The clinical efficacy,5-year survival and incidence of adverse drug reactions of two groups were observed.RESULTS:The total effective rate of observation group and control group were respectively 95.56％ (43/45) and 93.33 (42/45),yet the 5-year survival rate were respectively 88.89％ (40/45) and 86.67％ (39/45),without any statistical significance between two groups (P ＞ 0.05).The incidence of adverse drug reactions of observation group was 4.44％ (2/45),significantly lower than that of control group 20.00％ (9/45),with statistically significant difference (P ＜ 0.05).CONCLUSIONS:The efficacy of paclitaxel combined with oxaliplatin in treatment of advanced and recurrent cervical cancer is significant with few adverse drug reactions and high safety.%目的:探讨紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效与安全性.方法:选取2011年2月-2012年3月福建医科大学附属龙岩第一医院收治的晚期与复发性宫颈癌患者90例,以随机数字表法分为观察组和对照组,每组45例.对照组患者给予紫杉醇联合顺铂,观察组患者给予紫杉醇联合奥沙利铂.观察两组患者的临床疗效、5年生存情况和不良反应发生情况.结果:观察组、对照组患者的总有效率分别为95.56％ (43/45)、93.33(42/45),5年生存率分别为88.89％ (40/45)、86.67％(39/45),两组的差异均无统计学意义(P＞0.05).观察组患者不良反应发生率为4.44％ (2/45),明显低于对照组的20.00％(9/45),差异有统计学意义(P＜0.05).结论:紫杉醇联合奥沙利铂治疗晚期与复发性宫颈癌的疗效较好,不良反应少,安全性高.